Clinical Trials Medical Science Liaison

We are building a new international team to support an innovative oncology clinical development programme focused on multiple myeloma and are looking for a Clinical Trials Medical Science Liaison based in Australia.

Working across the Asia-Pacific region, you will engage with oncologists, principal investigators, study physicians, KOLs and clinical trial sites, helping to strengthen scientific collaboration throughout the clinical development process.

Responsibilities

• Develop trusted scientific partnerships with investigators, oncologists, KOLs and clinical trial sites.
• Support clinical trial patient recruitment and enrolment through scientific engagement with investigators and site teams.
• Provide field-based scientific support for oncology clinical development programmes.
• Facilitate scientific exchange between investigators, study sites and internal clinical development teams.
• Support investigator meetings and ongoing site engagement.
• Gather actionable medical and investigator insights to help inform study strategy.
• Remain at the forefront of emerging oncology and multiple myeloma data, treatment pathways and clinical research.
• Collaborate as part of an international team to support successful study execution.

Requirements

• PhD, PharmD, MD, oncology-focused MSc or another relevant advanced scientific/healthcare qualification.
• Strong oncology and/or haematology-oncology clinical trials experience.
• Experience as a Clinical Trials MSL is highly desirable.
• Strong understanding of clinical development and the drug development process.
• Confidence interpreting and communicating complex scientific and clinical data.
• Experience engaging investigators, oncologists, KOLs and other scientific stakeholders.
• Excellent scientific communication and stakeholder management skills.
• Ability to work independently across a regional territory.
• Fluency in English and flexibility for regular domestic and international travel.

Experience within multiple myeloma, investigational oncology medicines or regional APAC Medical Affairs/Clinical Development would be particularly valuable.